speb/financial-data huggingface dataset:
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -171700000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Repurchase Of Capital Stock: 0.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Research And Development: 756300000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 37100000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Restructuring And Mergern Acquisition: 986600000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 268014200000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 1770400000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 602800000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 16847200000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 25024100000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Share Issued: 585938609.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Special Income Charges: -2875700000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 298428000000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 257661900000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: -795131050.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Tax Provision: 12110200000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.28
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Taxes Receivable: 56700000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -17666400000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Assets: 450715100000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 319777000000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Debt: 66476300000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 298508000000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Total Expenses: 242629700000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 152207100000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 208658800000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 30215800000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 216200000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 2490100000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Total Unusual Items: -2875700000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: -2875700000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Tradeand Other Payables Non Current: 1200000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Work In Process: 15770300000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Working Capital: 120065000000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Write Off: 2298100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 44331300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 53882800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Assets Held For Sale Current: 0.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 7187600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 3363800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 580800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 39039700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 75225600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 580800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 308783900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 34966000000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 262256400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 934300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 61428800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 62363100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 143405800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 3045800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 6299900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 40085600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 149241300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 104318600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 389692600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 7187600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 2429500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 19479900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 21909400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Equity Investment: 898900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 2473700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Minority Interest: 65700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 41869000000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 149241300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 268698300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 12033100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 3706900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 580801623.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 28690600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 6691900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 308203100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 33785700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 2607600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Liabilities: 456100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 114275300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Receivables: 138800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 36185900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Payables: 47967600000.00
AUROPHARMA.NS income_statement (quarterly, 2024-09-30) — Restructuring And Mergern Acquisition: 0.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 580801623.00
AUROPHARMA.NS income_statement (quarterly, 2024-09-30) — Special Income Charges: 0.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 308783900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 268698300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Taxes Receivable: 0.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 480944500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 328263800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 84272500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 308849600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 172094900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 218688100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 28689100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 3636300000.00
AUROPHARMA.NS income_statement (quarterly, 2024-09-30) — Total Unusual Items: 0.00
AUROPHARMA.NS income_statement (quarterly, 2024-09-30) — Total Unusual Items Excluding Goodwill: 0.00
AUROPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 118850600000.00
AUROPHARMA.NS income_statement (quarterly, 2024-09-30) — Write Off: 0.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 33684600000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 78931500000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 580913462.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Basic EPS: 14.56
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 33154100000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 4185300000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 4185300000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 580913462.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Diluted EPS: 14.56
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 8458100000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — EBIT: 13183300000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — EBITDA: 17368600000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 45777400000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 1184800000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 1184800000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Minority Interests: 2400000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income: 8458100000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 8458100000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 8455700000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 8458100000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 8458100000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 8455700000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: -1184800000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -1184800000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 17368600000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Normalized Income: 8458100000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Operating Income: 12092800000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 78931500000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 1572900000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 19037500000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Pretax Income: 11998500000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 33154100000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 4185300000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Special Income Charges: 0.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Tax Provision: 3542800000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.30
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 66838700000.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items: 0.00
AUROPHARMA.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: 0.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — +Operating Expense: 133958700000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 36057500000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — +Total Revenue: 313781300000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 83811200000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 41888500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 41888500000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 57459300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 57459300000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -65384700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -65384700000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 1872400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 1872400000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -1096800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -1096800000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Amortization: 4630300000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 4630300000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Assets Held For Sale Current: 0.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Assets Held For Sale Current: 0.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 502700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 502700000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 582825614.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 580636247.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Basic EPS: 59.81
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 15.56
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 33854300000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 47354300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 47354300000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -25195500000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 3211900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 3211900000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 580800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 580800000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 55689500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 55689500000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 81985800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 81985800000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -10400000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 28149100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 28149100000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 27540400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 27540400000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -7354900000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: -3400000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: 6053300000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Payable: -3108900000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -8620800000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -12444800000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Changes In Cash: 21686000000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Common Stock: 580800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 580800000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 326533200000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 326533200000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Common Stock Payments: -9302400000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 34445500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 34445500000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 130262400000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 34278800000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Assets: 271624600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 271624600000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 819800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 819800000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Debt: 63800300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 63800300000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 64620100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 64620100000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Deferred Taxes Liabilities: 2849300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Deferred Taxes Liabilities: 2849300000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 146823400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 146823400000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 2755600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 2755600000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Defined Pension Benefit: 1400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Defined Pension Benefit: 1400000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Depreciation: 16494200000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 16494200000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 16494200000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 4444300000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 16494200000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 4444300000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 582825614.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 580636247.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Diluted EPS: 59.81
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 15.56
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 34858800000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 9034700000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 19800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 19800000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Dividends Received Cfi: 0.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — EBIT: 55235300000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — EBIT: 14501100000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — EBITDA: 71729500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — EBITDA: 18945400000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: 91000000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — End Cash Position: 55637900000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 151400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 151400000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: 1197800000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 51980600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 51980600000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 14050700000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -367000000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: 89400000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 8735800000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Goodwill: 6180200000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 6180200000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 42387200000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 42387200000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 58556100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 58556100000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 221723900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 221723900000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Gross Profit: 183518900000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 49532400000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Hedging Assets Current: 0.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 0.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Held To Maturity Securities: 527500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Held To Maturity Securities: 527500000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Impairment Of Capital Assets: 696400000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Interest Expense: 4572400000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 1150200000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 4572400000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 1150200000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Interest Income: 3532400000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 3532400000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -4203200000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 3473700000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Inventories Adjustments Allowances: 0.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Inventories Adjustments Allowances: 0.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Inventory: 105437200000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 105437200000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 405950000000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 405950000000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -18758000000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 1181600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 1181600000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Investmentsin Associatesat Cost: 97200000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investmentsin Associatesat Cost: 97200000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Investmentsin Joint Venturesat Cost: 1238200000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investmentsin Joint Venturesat Cost: 1238200000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 6614300000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 10073400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 10073400000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 2392100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 2392100000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 15616500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 15616500000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 18008600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 18008600000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 6614300000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: -11188600000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Equity Investment: 1335400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 1335400000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 2829300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 2829300000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 129850700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 129850700000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Minority Interest: -63900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: -63900000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Minority Interests: 23100000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Minority Interests: 6400000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Net Business Purchase And Sale: -113900000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: -9302400000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Net Debt: 23727300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 23727300000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: 755900000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Net Income: 34858800000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income: 9034700000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 34858800000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 9034700000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 34835700000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 9028300000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 34858800000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 9034700000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 34858800000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 9034700000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 50662900000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 34835700000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 9028300000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Net Intangibles Purchase And Sale: -5516900000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Net Interest Income: -4572400000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -1150200000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 881600000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: 16037100000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: -4574300000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -4572400000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -1150200000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Net Other Financing Charges: -225000000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Net Other Investing Changes: 2167700000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Net PPE: 156339200000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 156339200000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -19650200000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: 20611400000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 284146000000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 284146000000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Revenue: 475700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 475700000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 12929600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 12929600000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 3032700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 3032700000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 2829300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 2829300000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 6798100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 6798100000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 71729500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 18945400000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Normalized Income: 34858800000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 9034700000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 39246200000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Operating Income: 49560200000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Operating Income: 13474900000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Operating Revenue: 313781300000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 83811200000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 580801623.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 580801623.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Other Cash Adjustment Outside Changein Cash: 6600000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 23570200000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 23570200000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 2071900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 2071900000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 325952400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 325952400000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 36207000000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 36207000000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Inventories: 4618900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Inventories: 4618900000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: 750000000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 600000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: 545400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 545400000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 6218500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 1232100000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 76164300000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 19996800000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Payable: 8113500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 8113500000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Properties: 121894300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 121894300000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 6557100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 6557100000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 26296300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 26296300000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Other Special Charges: 89400000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Payables: 50021800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Payables: 50021800000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 2755600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 2755600000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 19677500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 19677500000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Pretax Income: 50662900000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 13350900000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 188000000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of Business: -113900000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of Intangibles: -5516900000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -230200000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -19678600000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 32453000000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 32453000000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 130262400000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 34278800000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 16494200000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 4444300000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 713400000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 713400000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -11188600000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Repurchase Of Capital Stock: -9302400000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Research And Development: 951000000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 369200000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 369200000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Restructuring And Mergern Acquisition: 0.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 302216500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 302216500000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 1111800000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 28400000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 21850600000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 30586400000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Share Issued: 580801623.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 580801623.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Special Income Charges: 0.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 326533200000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 326533200000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 284146000000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 284146000000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Tax Provision: 15827200000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 4322600000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.31
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.32
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 27800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 27800000.00
AUROPHARMA.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -17313500000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Assets: 497849700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 497849700000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 342149700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 342149700000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Debt: 82628700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 82628700000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 326469300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 326469300000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Total Expenses: 264221100000.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 70336300000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 171380400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 171380400000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 226225100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 226225100000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 24557000000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 24557000000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 168500000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 2849300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 2849300000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 0.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
AUROPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Tradeand Other Payables Non Current: 69700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Tradeand Other Payables Non Current: 69700000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Work In Process: 16384700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 16384700000.00
AUROPHARMA.NS balance_sheet (annual, 2025-03-31) — Working Capital: 124801200000.00
AUROPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 124801200000.00
AUROPHARMA.NS income_statement (annual, 2025-03-31) — Write Off: 134000000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 33548300000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 77917700000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 580809859.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 14.20
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 32392200000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 4057000000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 4057000000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 580809859.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 14.20
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 8247500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — EBIT: 13045500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — EBITDA: 17102500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 45525500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 977500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 977500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Minority Interests: 5500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income: 8247500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 8247500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 8242000000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 8247500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 8247500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 8242000000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -977500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -977500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 17102500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 8247500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Operating Income: 11977200000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 77917700000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 1053000000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 17967000000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 12068000000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 32392200000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 4057000000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 3826000000.00
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.32
AUROPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 65940500000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 38146900000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 86045100000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 580912572.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 15.67
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 34812100000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 4647300000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 4647300000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 580912572.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 15.67
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 9102900000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — EBIT: 14312900000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — EBITDA: 18960200000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 51233000000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 927700000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 927700000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Minority Interests: 4900000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income: 9102900000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 9102900000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 9098000000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 9102900000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 9102900000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 9098000000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -927700000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -927700000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 19613500000.00